Total Payments
$28,867
2024 Payments
$5,203
Companies
54
Transactions
1,152
Medicare Patients
6,939
Medicare Billing
$825,520
Payment Breakdown by Category
Food & Beverage$16,977 (58.8%)
Consulting$7,836 (27.1%)
Research$2,712 (9.4%)
Travel$875.11 (3.0%)
Education$388.23 (1.3%)
Other$79.27 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $16,977 | 1,115 | 58.8% |
| Consulting Fee | $7,836 | 7 | 27.1% |
| Unspecified | $2,712 | 7 | 9.4% |
| Travel and Lodging | $875.11 | 5 | 3.0% |
| Education | $388.23 | 15 | 1.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $79.27 | 3 | 0.3% |
Payments by Type
General
$26,156
1,145 transactions
Research
$2,712
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $8,088 | 217 | $0 (2024) |
| Amgen Inc. | $5,049 | 121 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,786 | 104 | $0 (2024) |
| Boehringer Ingelheim b.v. | $1,608 | 3 | $0 (2017) |
| PFIZER INC. | $1,255 | 92 | $0 (2024) |
| Lilly USA, LLC | $1,133 | 76 | $0 (2024) |
| West-Ward Pharmaceuticals | $965.17 | 3 | $0 (2018) |
| SANOFI-AVENTIS U.S. LLC | $849.53 | 54 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $737.09 | 48 | $0 (2023) |
| ABBVIE INC. | $726.69 | 42 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,203 | 117 | Amgen Inc. ($3,484) |
| 2023 | $2,213 | 133 | AstraZeneca Pharmaceuticals LP ($315.69) |
| 2022 | $4,526 | 156 | Novo Nordisk Inc ($2,219) |
| 2021 | $4,781 | 171 | Novo Nordisk Inc ($2,265) |
| 2020 | $3,548 | 126 | Novo Nordisk Inc ($1,875) |
| 2019 | $1,910 | 128 | Novo Nordisk Inc ($344.85) |
| 2018 | $2,353 | 170 | Novo Nordisk Inc ($540.69) |
| 2017 | $4,335 | 151 | Boehringer Ingelheim b.v. ($1,608) |
All Payment Transactions
1,152 individual payment records from CMS Open Payments — Page 1 of 47
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $17.78 | General |
| Category: VACCINES | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.53 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/02/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $20.61 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 11/18/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.62 | General |
| Category: Diabetes | ||||||
| 11/11/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $17.75 | General |
| Category: UROLOGY | ||||||
| 11/07/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $12.00 | General |
| Category: Diabetes | ||||||
| 11/06/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $27.31 | General |
| Category: Diabetes | ||||||
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.63 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/29/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $24.14 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/28/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: NEUROSCIENCE | ||||||
| 10/22/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 10/16/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $23.14 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/15/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $12.21 | General |
| Category: Diabetes | ||||||
| 10/10/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $28.88 | General |
| Category: Diabetes | ||||||
| 10/08/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.78 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/07/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: Biological | ||||||
| 10/05/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Consulting Fee | Cash or cash equivalent | $2,136.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/05/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Travel and Lodging | In-kind items and services | $238.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/05/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Travel and Lodging | In-kind items and services | $196.21 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/05/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Travel and Lodging | In-kind items and services | $175.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/05/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Travel and Lodging | In-kind items and services | $175.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/05/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Travel and Lodging | In-kind items and services | $90.90 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/05/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $48.89 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/05/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $39.99 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/05/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $21.65 | General |
| Category: Inflammation/Rare Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| safety and efficacy linagliptin vs SU | Boehringer Ingelheim b.v. | $1,608 | 2 |
| Opioid PMR Study | West-Ward Pharmaceuticals | $965.17 | 3 |
| A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) | Takeda Pharmaceuticals U.S.A., Inc. | $138.20 | 1 |
| CARMELINA | Boehringer Ingelheim b.v. | $0.74 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 1,624 | 3,360 | $429,670 | $232,395 |
| 2022 | 32 | 1,769 | 3,189 | $390,300 | $207,424 |
| 2021 | 30 | 1,783 | 3,441 | $372,755 | $201,629 |
| 2020 | 35 | 1,763 | 3,315 | $368,870 | $184,072 |
Total Patients
6,939
Total Services
13,305
Medicare Billing
$825,520
Procedure Codes
121
All Medicare Procedures & Services
121 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 83 | 681 | $102,150 | $65,730 | 64.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 199 | 384 | $57,600 | $33,265 | 57.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 103 | 180 | $40,500 | $25,313 | 62.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 60 | 380 | $38,000 | $24,385 | 64.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 175 | 175 | $43,750 | $22,571 | 51.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 91 | 149 | $52,150 | $13,836 | 26.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 70 | 98 | $19,600 | $12,220 | 62.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 118 | 198 | $24,750 | $11,766 | 47.5% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 20 | 27 | $10,800 | $5,986 | 55.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 258 | 506 | $5,060 | $4,233 | 83.6% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 44 | 44 | $3,740 | $3,165 | 84.6% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 21 | 38 | $4,750 | $1,894 | 39.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 47 | 47 | $1,410 | $1,382 | 98.0% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 46 | 52 | $4,160 | $1,216 | 29.2% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 66 | 66 | $1,650 | $1,214 | 73.6% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2023 | 55 | 70 | $3,500 | $864.50 | 24.7% |
| 76700 | Complete ultrasound scan of abdomen | Office | 2023 | 16 | 16 | $2,800 | $837.34 | 29.9% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Office | 2023 | 16 | 16 | $2,800 | $802.66 | 28.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 54 | 66 | $3,630 | $660.02 | 18.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 16 | 18 | $1,350 | $586.36 | 43.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 17 | 37 | $1,110 | $406.08 | 36.6% |
| 81003 | Automated urinalysis test | Office | 2023 | 14 | 16 | $240.00 | $35.20 | 14.7% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 11 | 18 | $270.00 | $20.91 | 7.7% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 24 | 78 | $3,900 | $6.65 | 0.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 92 | 592 | $88,800 | $49,251 | 55.5% |
About Dr. Jay Sandberg, D.O
Dr. Jay Sandberg, D.O is a Internal Medicine healthcare provider based in Troy, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1548293483.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jay Sandberg, D.O has received a total of $28,867 in payments from pharmaceutical and medical device companies, with $5,203 received in 2024. These payments were reported across 1,152 transactions from 54 companies. The most common payment nature is "Food and Beverage" ($16,977).
As a Medicare-enrolled provider, Sandberg has provided services to 6,939 Medicare beneficiaries, totaling 13,305 services with total Medicare billing of $825,520. Data is available for 4 years (2020–2023), covering 121 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Troy, MI
- Active Since 07/07/2006
- Last Updated 09/15/2008
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1548293483
Products in Payments
- RYBELSUS (Drug) $3,680
- KRYSTEXXA (Biological) $3,667
- Rybelsus (Drug) $2,183
- TRADJENTA (Drug) $1,635
- FARXIGA (Drug) $1,028
- Morphine Sulfate ER tablets (Drug) $888.25
- XIFAXAN (Drug) $812.25
- EVENITY (Biological) $759.15
- Ozempic (Drug) $644.88
- ELIQUIS (Drug) $563.18
- XARELTO (Drug) $558.45
- Victoza (Drug) $543.22
- TRULICITY (Drug) $433.83
- UBRELVY (Drug) $394.57
- Saxenda (Drug) $392.92
- Aimovig (Biological) $331.57
- TRELEGY ELLIPTA (Drug) $328.08
- SOLIQUA 100/33 (Biological) $312.51
- VRAYLAR (Drug) $282.59
- BREZTRI (Drug) $267.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Troy
Dr. Neil Fraser, Md, MD
Internal Medicine — Payments: $180,276
Internal Medicine $180,276
Dr. John Calado, Do, DO
Internal Medicine — Payments: $152,221
Internal Medicine $152,221
Michael Doyle, Md, MD
Internal Medicine — Payments: $85,884
Internal Medicine $85,884
Dr. Mohammed Kabir, Md, MD
Internal Medicine — Payments: $26,648
Internal Medicine $26,648
Dr. Noor Bunney, Md, MD
Internal Medicine — Payments: $21,394
Internal Medicine $21,394
Dr. Stephen Renzi, D.o, D.O
Internal Medicine — Payments: $14,760
Internal Medicine $14,760